ERCC1 and cancer: It also has an important role in removal of the particularly toxic, and so therapeutically very effective, interstrand crosslinks (ICLs, reviewed in [4]) Since the most commonly used cancer chemotherapeutics, platinating agents such as cisplatin and carboplatin, cause all three types of lesion, there has been intense interest in the use of ERCC1 as a predictive marker of therapeutic response to these agents.